Weekly Research Analysts’ Ratings Changes for Beigene (BGNE)

A number of firms have modified their ratings and price targets on shares of Beigene (NASDAQ: BGNE) recently:

  • 1/5/2018 – Beigene was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 1/3/2018 – Beigene was given a new $120.00 price target on by analysts at Maxim Group. They now have a “buy” rating on the stock.
  • 1/3/2018 – Beigene was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 12/18/2017 – Beigene was given a new $120.00 price target on by analysts at Maxim Group. They now have a “buy” rating on the stock.
  • 12/11/2017 – Beigene had its “buy” rating reaffirmed by analysts at Cowen Inc.
  • 12/11/2017 – Beigene was given a new $120.00 price target on by analysts at Maxim Group. They now have a “buy” rating on the stock. They wrote, “BeiGene presented initial data from the ongoing Phase 1b trial of its BTK inhibitor (BGB-3111), in combination with its investigational anti-PD-1 antibody, BGB-A317, in patients with B-cell malignancies at the ASH Annual Meeting.””
  • 11/14/2017 – Beigene was given a new $120.00 price target on by analysts at Maxim Group. They now have a “buy” rating on the stock.
  • 11/14/2017 – Beigene had its “buy” rating reaffirmed by analysts at Cowen Inc. They wrote, “SGMO reported 3Q17 results and is on track to report first data from the Ph1/2 trials.””
  • 11/14/2017 – Beigene had its “neutral” rating reaffirmed by analysts at Robert W. Baird. They now have a $83.00 price target on the stock, up previously from $58.00.
  • 11/13/2017 – Beigene was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company’s clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands. “

Beigene Ltd (NASDAQ BGNE) traded down $1.98 during trading on Friday, reaching $100.39. 80,200 shares of the company were exchanged, compared to its average volume of 156,233. Beigene Ltd has a 1 year low of $30.02 and a 1 year high of $118.95. The company has a quick ratio of 9.27, a current ratio of 9.33 and a debt-to-equity ratio of 0.20. The firm has a market cap of $4,540.00 and a price-to-earnings ratio of -76.63.

Beigene (NASDAQ:BGNE) last announced its earnings results on Monday, November 13th. The company reported $2.54 EPS for the quarter, topping the consensus estimate of $0.23 by $2.31. The firm had revenue of $220.21 million during the quarter, compared to the consensus estimate of $1.55 million. During the same quarter last year, the business earned ($1.08) EPS. equities analysts expect that Beigene Ltd will post -2.04 earnings per share for the current year.

In other Beigene news, CEO John Oyler sold 150,957 shares of the business’s stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $80.50, for a total value of $12,152,038.50. Following the completion of the transaction, the chief executive officer now directly owns 491,891 shares of the company’s stock, valued at $39,597,225.50. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CMO Amy C. Peterson sold 3,601 shares of the business’s stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $82.96, for a total transaction of $298,738.96. Following the completion of the transaction, the chief marketing officer now directly owns 1,201 shares of the company’s stock, valued at $99,634.96. The disclosure for this sale can be found here. Insiders sold a total of 483,482 shares of company stock worth $42,139,474 over the last 90 days. Company insiders own 19.90% of the company’s stock.

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.

Receive News & Ratings for Beigene Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene Ltd and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply